Jonathan Synett

Jonathan Synett has a diverse work experience in the healthcare industry. Jonathan is currently the Chief Investment Officer at NCL Investment Management, focusing on early-stage healthcare start-ups. Jonathan has also held Non Executive Director roles at Ampersand Health, Azadyne Ltd, Viramal Limited, Alert Technology Ltd, Avvinity Therapeutics Limited, Centauri Therapeutics Limited, and Immune Regulation Ltd. Furthermore, they have served as a Board Observer at Curesponse and TC BioPharm Limited. Overall, Jonathan's work experience showcases their expertise in investing in healthcare technologies and their involvement in the development of digital medicines, immunotherapies, and immune system reset technologies.

Jonathan Synett has a diverse education history. In 1984, they began their education at Habs, where they studied without completing a specific degree or field of study until 1995. Following this, from 1996 to 1999, they attended the University of Manchester, where they obtained a Bachelor of Arts in History and Economics. Finally, in 2006, they attended INSEAD to pursue a Master of Business Administration (MBA) with a focus on General Management.